San Diego, CA, United States of America

Anthony Manibusan

This inventor holds 5 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Merck Sharp + Dohme Corp., Ambrx, Inc., Ambryx, Inc.. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony Manibusan. Retrieved from https://idiyas.com/inventor/anthony-manibusan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Anthony Manibusan: Pioneering Inventor from San Diego

Introduction: Anthony Manibusan is a renowned inventor based in San Diego, CA, known for his groundbreaking contributions to various industries.

Latest Patents: Anthony Manibusan holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of innovative ideas.

Career Highlights: With over two decades of experience in the innovation sector, Anthony Manibusan has successfully brought numerous inventions to market, revolutionizing the way we approach everyday challenges.

Collaborations: Throughout his career, Anthony Manibusan has collaborated with leading research institutions, universities, and companies to further develop his inventions and bring them to fruition on a global scale.

Conclusion: Anthony Manibusan's passion for innovation and his relentless drive to create solutions that make a difference have solidified his reputation as a trailblazing inventor in San Diego and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…